CTOs on the Move

Volpara Health

www.volpara.com

 
Volpara Health provides an advanced AI software platform that enables a high-quality, optimized and personalized cancer screening experience. From the time a patient enters a clinic to the moment they obtain key results, the Volpara Breast Health Platform collects and analyzes information to better understand a patient`s breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities. More than thirteen million women across 39 countries have had their breast density assessed by Volpara. The company`s software is installed in approximately 2000 leading facilities worldwide, including top cancer centers in the United States. Volpara Health`s technology has been the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.volpara.com
  • 19000 33rd Avenue W Suite 130
    Lynnwood, WA USA 98036
  • Phone: 800.305.3865

Executives

Name Title Contact Details

Similar Companies

Terra Nova Transcription

Terra Nova Transcription is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Society of Anesthesiologists

The American Society of Anesthesiologists is an educational, research and scientific association of physicians organized to raise the standards of the medical practice of anesthesiology and to improve patient care.

Environmental Health

Environmental Health is a Newton Center, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.

Minnesota Visiting Nurse Agency

MVNA serves individuals and families that are economically disadvantaged and at high risk for critical social and health issues. More than 90% of MVNA clients residing in Minneapolis are living at or below 200% of Federal Poverty Guidelines. Many of